Literature DB >> 22056317

Focal adhesion kinase governs cardiac concentric hypertrophic growth by activating the AKT and mTOR pathways.

C F M Z Clemente1, J Xavier-Neto, A P Dalla Costa, S R Consonni, J E Antunes, S A Rocco, M B Pereira, C C Judice, B Strauss, P P Joazeiro, J R Matos-Souza, K G Franchini.   

Abstract

The heart responds to sustained overload by hypertrophic growth in which the myocytes distinctly thicken or elongate on increases in systolic or diastolic stress. Though potentially adaptive, hypertrophy itself may predispose to cardiac dysfunction in pathological settings. The mechanisms underlying the diverse morphology and outcomes of hypertrophy are uncertain. Here we used a focal adhesion kinase (FAK) cardiac-specific transgenic mice model (FAK-Tg) to explore the function of this non-receptor tyrosine kinase on the regulation of myocyte growth. FAK-Tg mice displayed a phenocopy of concentric cardiac hypertrophy, reflecting the relative thickening of the individual myocytes. Moreover, FAK-Tg mice showed structural, functional and molecular features of a compensated hypertrophic growth, and preserved responses to chronic pressure overload. Mechanistically, FAK overexpression resulted in enhanced myocardial FAK activity, which was proven by treatment with a selective FAK inhibitor to be required for the cardiac hypertrophy in this model. Our results indicate that upregulation of FAK does not affect the activity of Src/ERK1/2 pathway, but stimulated signaling by a cascade that encompasses PI3K, AKT, mTOR, S6K and rpS6. Moreover, inhibition of the mTOR complex by rapamycin extinguished the cardiac hypertrophy of the transgenic FAK mice. These findings uncover a unique role for FAK in regulating the signaling mechanisms that governs the selective myocyte growth in width, likely controlling the activity of PI3K/AKT/mTOR pathway, and suggest that FAK activation could be important for the adaptive response to increases in cardiac afterload. This article is part of a Special Issue entitled "Local Signaling in Myocytes".
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056317     DOI: 10.1016/j.yjmcc.2011.10.015

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  27 in total

1.  Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip.

Authors:  Megan L McCain; Sean P Sheehy; Anna Grosberg; Josue A Goss; Kevin Kit Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

2.  Gene expression patterns in transgenic mouse models of hypertrophic cardiomyopathy caused by mutations in myosin regulatory light chain.

Authors:  Wenrui Huang; Katarzyna Kazmierczak; Zhiqun Zhou; Vanessa Aguiar-Pulido; Giri Narasimhan; Danuta Szczesna-Cordary
Journal:  Arch Biochem Biophys       Date:  2016-02-22       Impact factor: 4.013

3.  Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin.

Authors:  David S Paul; Trisha J Grevengoed; Florencia Pascual; Jessica M Ellis; Monte S Willis; Rosalind A Coleman
Journal:  Biochim Biophys Acta       Date:  2014-03-12

4.  Variation in stiffness regulates cardiac myocyte hypertrophy via signaling pathways.

Authors:  Jieli Li; Michael A Mkrtschjan; Ying-Hsi Lin; Brenda Russell
Journal:  Can J Physiol Pharmacol       Date:  2016-06-15       Impact factor: 2.273

5.  Low-load blood flow restriction elicits greater concentric strength than non-blood flow restriction resistance training but similar isometric strength and muscle size.

Authors:  Ethan C Hill; Terry J Housh; Joshua L Keller; Cory M Smith; John V Anders; Richard J Schmidt; Glen O Johnson; Joel T Cramer
Journal:  Eur J Appl Physiol       Date:  2019-12-17       Impact factor: 3.078

6.  The mTOR-FAK mechanotransduction signaling axis for focal adhesion maturation and cell proliferation.

Authors:  Fan-Yen Lee; Yen-Yi Zhen; Chun-Man Yuen; Raymond Fan; Yen-Ta Chen; Jiunn-Jye Sheu; Yi-Ling Chen; Ching-Jen Wang; Cheuk-Kwan Sun; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

7.  Isorhamnetin protects against cardiac hypertrophy through blocking PI3K-AKT pathway.

Authors:  Lu Gao; Rui Yao; Yuzhou Liu; Zheng Wang; Zhen Huang; Binbin Du; Dianhong Zhang; Leiming Wu; Lili Xiao; Yanzhou Zhang
Journal:  Mol Cell Biochem       Date:  2017-02-07       Impact factor: 3.396

8.  The prevalent I686T human variant and loss-of-function mutations in the cardiomyocyte-specific kinase gene TNNI3K cause adverse contractility and concentric remodeling in mice.

Authors:  Peiheng Gan; Catalin Baicu; Hirofumi Watanabe; Kristy Wang; Ge Tao; Daniel P Judge; Michael R Zile; Takako Makita; Rupak Mukherjee; Henry M Sucov
Journal:  Hum Mol Genet       Date:  2021-01-06       Impact factor: 6.150

9.  Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.

Authors:  Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers
Journal:  Metabolism       Date:  2013-01-24       Impact factor: 8.694

10.  Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway.

Authors:  Hannah Crossland; Abid A Kazi; Charles H Lang; James A Timmons; Philippe Pierre; Daniel J Wilkinson; Kenneth Smith; Nathaniel J Szewczyk; Philip J Atherton
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-21       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.